Breaking News

New Cardiac Lead Remover Promised to Have a Lighter Touch

April 26, 2012

Spectranetics will release the device on a small scale first.

The Spectranetics Corporation has received approval from the U.S. Food and Drug Administration for its new GlideLight Laser Sheath, used for the removal of cardiac leads.

The GlideLight is touted to deliver precise control, reducing the need for excess force to be exerted, making lead extraction safer. GlideLight is effectively the second-generation version of Spectranetics’ existing device, the SLS II. According to the company, GlideLight requires 55 percent less force to operate than the SLS II.

“Mechanical force is a leading cause of complications during lead extraction,” said Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, “and reduced force improves the control for safely removing leads. It is particularly important to have control when breaking up tough binding sites.” Wilkoff is a non-paid member of Spectranetics’ medical advisory board.

The first person to use the device proved satisfied by its performance: Dr. Charles Kennergren, professor at Sahlgrenska University Hospital in Gothenburg, Sweden, said that he is “very impressed with the reduced force and increased control and efficiency that GlideLight has provided [him].”

GlideLight will be released on a broad, controlled scale only after it goes through a limited market release to gain early experience.

Spectranetics is based in Colorado Spring, Colo., and provides single-use medical devices used in minimally invasive procedures within the cardiovascular system.
blog comments powered by Disqus
  • Where to Conduct Early Feasibility Studies

    Where to Conduct Early Feasibility Studies

    Karim Benali, M.D., Msc||May 2, 2016
    Why you shouldn’t rule out the United States.

  • A Grand Vision for Better Healthcare

    A Grand Vision for Better Healthcare

    Ellyn McMullin, Research Associate & Daniel R. Matlis, President, Axendia Inc.||April 29, 2016
    IBM wants to transform the medical industry.

  • It’s Time We Support Our Veterans

    It’s Time We Support Our Veterans

    Emily L. Cross, Ph.D., Director of Media and Communication, TecMed Inc.||April 12, 2016
    Diabetes is a significant problem in this population and it’s time to facilitate the development of technology solutions.